Dr. Reddy’s Q4 Results Drug manufacturer declares dividend net profit increases by one third but falls short of analyst estimates.

Results for Dr. Reddy’s Q4:

On Tuesday, the Hyderabad-based pharmaceutical business Dr. Reddy’s Laboratories (DRREDDY) revealed a consolidated net profit of Rs. 1,307 crore for the quarter that concluded on March 31. This represents an increase of 36.3% year over year when compared to the same period last year.

According to a regulatory filing, the pharmaceutical company reported revenue of Rs 7,083 crore for the January-March quarter, up 12.5% from the same period last year.

The March quarter net profit and revenue for Dr Reddy’s Labs were anticipated to be Rs 1,378 crore and Rs 7,359 crore, respectively, according to stock 24 news study.

According to the report

Revenue jumped 12.8% to Rs 6,119.1 crore from the company’s global generics business and 12.3% to Rs 1,152.6 crore from its pharmaceutical services and active ingredients unit.

The business reported that its fourth-quarter earnings before interest, taxes, depreciation, and amortisation (EBITDA) of Rs 1,872 crore accounted for 26.4% of its total revenue.

The pharmaceutical company’s quarterly EBITDA was estimated by Zee Business experts to be Rs 2,056 crore.

According to Dr. Reddy’s

Its India revenue fell by 12% year over year to Rs. 1,130 crore.
“Our expansion and financial success in. The year FY24 has been shaped by our US performance. Through licensing, teamwork, and pipeline development, we have also achieved great strides toward upcoming growth drivers,” GV Prasad, co-chairman of Dr. Reddy’s Labs, stated.

According to Dr. Reddy’s, its total income for the fiscal year increased by 14% to Rs. 27,916.4 crore.

Prasad continued, “We will invest in and develop the future growth drivers as we continue to strengthen our core businesses through superior execution.”